Wednesday, February 1, 2023
Mitochondrial Health

Alzheimer’s Disease: Transcranial Photobiomodulation for Mild Cognitive Impairment and Mild Dementia

In Feb 2022, Dr. Cassano presented this NYU-MGH study at LifeStance Health. The presentation covers in-vitro and pre-clinical data in support of the use of transcranial PBM for Alzheimer’s disease (AD). The most recent clinical data on PBM for AD were also reviewed. The NYU-MGH study was described: a large randomized, double-blind clinical trial (n=125) sponsored by NIH/NIA and by the Alzheimer’s Association.


Similar Posts

Leave a Reply

Your email address will not be published.